Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
FDA approves Vifor's hyperphosphatemia drug
Vifor Pharma has obtained federal approval for its Velphoro therapy for hyperphosphatemia in patients with chronic kidney disease who are undergoing dialysis. Data from a Phase III trial showed the drug fared better than Sanofi's Renvela in regulating phosphorus accumulation in the bloodstream.
Or we can send an email on your behalf